Aires Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-12-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.airespharma.com
Clinical Trials
13
Active:9
Completed:2
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT01725269
- Locations
- 🇺🇸
UCSD Medical Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Torrance, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Phase 2
Terminated
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: AIR001 (sodium nitrite inhalation solution)
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01725256
- Locations
- 🇺🇸
UCSD Medical Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Torrance, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary HypertensionPulmonary Arterial Hypertension
- Interventions
- Drug: 15 mg sodium nitrite inhalation solutionDrug: 25% MTD sodium nitrite inhalation solutionDrug: 90 mg sodium nitrite inhalation solutionDrug: 45 mg sodium nitrite inhalation solutionDrug: 120 mg sodium nitrite inhalation solution
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01409122
- Locations
- 🇺🇸
PAREXEL International Early Phase Clinical Unit - Baltimore, Baltimore, Maryland, United States
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Aires Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00814645
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
News
No news found